Retrophin, Inc. (NASDAQ:RTRX) today announced that Founder and CEO Martin Shkreli will present a corporate overview and update at the 16th Annual BIO CEO & Investor Conference being held February 10-11 in New York City.
Details of Retrophin’s presentation are as follows:
|Date:||Tuesday, February 11, 2014|
|Time:||9 a.m. Eastern Standard Time|
|Location:||The Waldorf Astoria New York|
A live webcast of the presentation will be available at www.retrophin.com in the Events & Presentations section. After the presentation, a replay will be archived and accessible for 90 days.
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's pipeline includes compounds for several catastrophic diseases, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.
|Trevena to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/3)|
|Transition Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/6)|
|ZIOPHARM Oncology to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/3)|
|Ohr Pharmaceutical to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference (2014/1/30)|
|Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City (2014/2/5)|
|Targacept to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|La Jolla Pharmaceutical Company to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/5)|
|CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City (2014/2/3)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.